CAR T-cell therapy for indolent lymphoma: a new treatment paradigm? Comment

被引：2
作者：
Holtzman, Noa G. [1 ]
Shah, Nirali N. [2 ]
机构：
[1] NCI, Immune Deficiency Cellular Therapy Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
LANCET ONCOLOGY | 2022年 / 23卷 / 01期
关键词：
D O I：
10.1016/S1470-2045(21)00648-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6 / 8
页数：4
相关论文
共 8 条
  • [1] A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
    Bachy, Emmanuel
    Maurer, Matthew J.
    Habermann, Thomas M.
    Gelas-Dore, Benedicte
    Maucort-Boulch, Delphine
    Estell, Jane A.
    Van den Neste, Eric
    Bouabdallah, Reda
    Gyan, Emmanuel
    Feldman, Andrew L.
    Bargay, Joan
    Delmer, Alain
    Slager, Susan L.
    da Silva, Maria Gomes
    Fitoussi, Olivier
    Belada, David
    Maisonneuve, Herve
    Intragumtornchai, Tanin
    Ansell, Stephen M.
    Lamy, Thierry
    Dartigues, Peggy
    Link, Brian K.
    Seymour, John F.
    Cerhan, James R.
    Salles, Gilles
    [J]. BLOOD, 2018, 132 (01) : 49 - 58
  • [2] Trends Analysis of Non-Hodgkin Lymphoma at the National, Regional, and Global Level, 1990-2019: Results From the Global Burden of Disease Study 2019
    Cai, Wenwen
    Zeng, Qingle
    Zhang, Xingxing
    Ruan, Weiqing
    [J]. FRONTIERS IN MEDICINE, 2021, 8
  • [3] Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial
    Frank, Matthew J.
    Hossain, Nasheed M.
    Bukhari, Ali
    Dean, Erin
    Spiegel, Jay Y.
    Claire, Gursharan K.
    Kirsch, Ilan
    Jacob, Allison P.
    Mullins, Chelsea D.
    Lee, Lik Wee
    Kong, Katherine A.
    Craig, Juliana
    Mackall, Crystal L.
    Rapoport, Aaron P.
    Jain, Michael D.
    Dahiya, Saurabh
    Locke, Frederick L.
    Miklos, David B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (27) : 3034 - +
  • [4] Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
    Jacobson, Caron A.
    Chavez, Julio C.
    Sehgal, Alison R.
    William, Basem M.
    Munoz, Javier
    Salles, Gilles
    Munshi, Pashna N.
    Casulo, Carla
    Maloney, David G.
    de Vos, Sven
    Reshef, Ran
    Leslie, Lori A.
    Yakoub-Agha, Ibrahim
    Oluwole, Olalekan O.
    Fung, Henry Chi Hang
    Rosenblatt, Joseph
    Rossi, John M.
    Goyal, Lovely
    Plaks, Vicki
    Yang, Yin
    Vezan, Remus
    Avanzi, Mauro P.
    Neelapu, Sattva S.
    [J]. LANCET ONCOLOGY, 2022, 23 (01) : 91 - 103
  • [5] Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
    Pastore, Alessandro
    Jurinovic, Vindi
    Kridel, Robert
    Hoster, Eva
    Staiger, Annette M.
    Szczepanowski, Monika
    Pott, Christiane
    Kopp, Nadja
    Murakami, Mark
    Horn, Heike
    Leich, Ellen
    Moccia, Alden A.
    Mottok, Anja
    Sunkavalli, Ashwini
    Van Hummelen, Paul
    Ducar, Matthew
    Ennishi, Daisuke
    Shulha, Hennady P.
    Hother, Christoffer
    Connors, Joseph M.
    Sehn, Laurie H.
    Dreyling, Martin
    Neuberg, Donna
    Moeller, Peter
    Feller, Alfred C.
    Hansmann, Martin L.
    Stein, Harald
    Rosenwald, Andreas
    Ott, German
    Klapper, Wolfram
    Unterhalt, Michael
    Hiddemann, Wolfgang
    Gascoyne, Randy D.
    Weinstock, David M.
    Weigert, Oliver
    [J]. LANCET ONCOLOGY, 2015, 16 (09) : 1111 - 1122
  • [6] Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016
    Qu, Xiaoyu
    Li, Hongli
    Braziel, Rita M.
    Passerini, Verena
    Rimsza, Lisa M.
    Hsi, Eric D.
    Leonard, John P.
    Smith, Sonali M.
    Kridel, Robert
    Press, Oliver
    Weigert, Oliver
    LeBlanc, Michael
    Friedberg, Jonathan W.
    Fang, Min
    [J]. BLOOD, 2019, 133 (01) : 81 - 93
  • [7] Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
    Sortais, Clara
    Lok, Anne
    Tessoulin, Benoit
    Gastinne, Thomas
    Mahe, Beatrice
    Dubruille, Viviane
    Blin, Nicolas
    Touzeau, Cyrille
    Moreau, Anne
    Bossard, Celine
    Peterlin, Pierre
    Garnier, Alice
    Guillaume, Thierry
    Le Bourgeois, Amandine
    Chevallier, Patrice
    Moreau, Philippe
    Leux, Christophe
    Le Gouill, Steven
    [J]. ANNALS OF HEMATOLOGY, 2020, 99 (07) : 1595 - 1604
  • [8] U.S. Food & Drug Administration, 2021, FDA GRANTS ACC APPR
1